Cellular immunity after alemtuzumab

Cellular immunity after alemtuzumab - ZINA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011205

Enrollment

Registered

2017-02-21

Start date

2017-02-27

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35

Interventions

Group 1: We will include 20 multiple sclerosis patients that are planned for alemtuzumab therapy in our study. For one year we will analyze monthly additional lab parameters during the mandatory bloo

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Multiple Sclerosis patients starting therapy with alemtuzumab

Exclusion criteria

Exclusion criteria: revocation of consent and underage patients

Design outcomes

Primary

Measure	Time frame
Analysis of innate immune cells and inflammatory mediators after Alemtuzumab therapy (primary endpoint: macrophage populations, macrophage polarizations with immunohistochemistry and flow cytomerty,	—

Secondary

Measure	Time frame
secondary endpoint: inflammatory parameters and mediators in the blood)	—

Countries

Germany

Contacts

Public ContactHelmar Lehmann

Universitätsklinikum Köln

helmar.lehmann@uk-koeln.de0221 478 87091

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026